The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies | Bentham Science
Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies

Author(s): Shivashni S. Gaundar and Linda J. Bendall

Volume 11, Issue 7, 2010

Page: [823 - 833] Pages: 11

DOI: 10.2174/138945010791320854

Price: $65

Open Access Journals Promotions 2
Abstract

The classical role of p38MAPK involves the transmission of death signals from stress stimuli such as ionizing radiation, inflammation and chemotherapy in normal and malignant cells. However emerging evidence points to having pleiotropic functions, ranging from cellular proliferation and survival, to cell cycle arrest and regulation of the tumor microenviroment. The mechanisms responsible for these diverse and rather contradictory functions of p38MAPK are only now being unraveled. In some hematological malignancies, p38MAPK is constitutively activated. The reasons for this are not fully understood, but can result from underlying genetic lesions such as the bcr/abl translocation. The involvement of p38MAPK in mediating cell cycle arrest in the face of cytotoxic damage suggests that p38MAPK may be a therapeutic target. The role of p38MAPK in cytokine production by the stromal compartment adds another level of complexity to the regulation of hematological malignancies that exhibit a degree of stromal dependence, at least some of which is cytokine driven. p38MAPK dependent cytokine production by malignant hematopoietic cells has also been observed, and promotes tumor cell adhesion, angiogenesis and osteoclastogenesis. This suggests a mutual relationship between tumor and stromal cells. In contrast, p38MAPK is required for the effects of cytotoxic agents in some hematological malignancies. These conflicting qualities point to the importance of careful consideration of the use of p38MAPK inhibitors as a therapeutic strategy.

Keywords: p38MAPK, hematological malignancy, bone marrow stroma, chemotherapy, proliferation, apoptosis


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy